Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain.
Knutson KL, Clynes R, Shreeder B, Yeramian P, Kemp KP, Ballman K, Tenner KS, Erskine CL, Norton N, Northfelt D, Tan W, Calfa C, Pegram M, Mittendorf EA, Perez EA. Knutson KL, et al. Among authors: clynes r. Cancer Res. 2016 Jul 1;76(13):3702-10. doi: 10.1158/0008-5472.CAN-15-3091. Epub 2016 Apr 20. Cancer Res. 2016. PMID: 27197192 Free PMC article. Clinical Trial.
Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.
Norton N, Fox N, McCarl CA, Tenner KS, Ballman K, Erskine CL, Necela BM, Northfelt D, Tan WW, Calfa C, Pegram M, Colon-Otero G, Perez EA, Clynes R, Knutson KL. Norton N, et al. Among authors: clynes r. Breast Cancer Res. 2018 Jun 14;20(1):52. doi: 10.1186/s13058-018-0989-8. Breast Cancer Res. 2018. PMID: 29898752 Free PMC article. Clinical Trial.
Redirected T Cell Cytotoxicity in Cancer Therapy.
Clynes RA, Desjarlais JR. Clynes RA, et al. Annu Rev Med. 2019 Jan 27;70:437-450. doi: 10.1146/annurev-med-062617-035821. Epub 2018 Oct 31. Annu Rev Med. 2019. PMID: 30379598 Review.
Novel technologies and emerging biomarkers for personalized cancer immunotherapy.
Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, Kvistborg P, Maccalli C, Maecker HT, Page DB, Robins H, Song W, Stack EC, Wang E, Whiteside TL, Zhao Y, Zwierzina H, Butterfield LH, Fox BA. Yuan J, et al. Among authors: clynes r. J Immunother Cancer. 2016 Jan 19;4:3. doi: 10.1186/s40425-016-0107-3. eCollection 2016. J Immunother Cancer. 2016. PMID: 26788324 Free PMC article. Review.
87 results